Pharmacological reasoning approach:
Clinical scenario: hypertension + peripheral edema + CKD.
Analysis of options:
Option A -- Aliskiren (direct renin inhibitor):
- Contraindicated in CKD, especially with ACE inhibitors or ARBs
- Risk: hyperkalemia, acute kidney injury -- NOT preferred
Option B -- Chlorthalidone (thiazide-like diuretic):
- Dual action: antihypertensive + diuretic (addresses both HTN and edema)
- Unlike HCTZ, chlorthalidone is effective even when GFR is 30-45 ml/min
- Longer half-life (45-60 hrs) than HCTZ -- better 24-hr BP control
- First-line antihypertensive per JNC guidelines
- PREFERRED in HTN + CKD + edema
Option C -- Prazosin (alpha-1 blocker):
- Causes first-dose hypotension
- No diuretic benefit; does not address edema
- Not first-line in CKD
Option D -- Beta blockers:
- Useful for HTN but no significant diuretic effect
- Not preferred when edema is the co-existing problem
\[\boxed{\text{Chlorthalidone}}\]